Fig. 2.

Reversal of immobility with pharmacological agents. a Dopamine (DA), serotonin (5-HT), octopamine (OCT), tyramine (TYR), and carbachol (Carb) were evaluated for their effects on spontaneous movement in the immobility assay at the concentrations shown in the graph. Zeroes are included in this figure to indicate results where columns are lacking. b The benzodiazepines clonazepam (CZPM) and diazepam (DZPM) and the antipsychotic drugs clozapine (Cloz), olanzapine (Olan), haloperidol (Halo), and sulpiride (Sulp) were tested for their effectiveness in reducing immobility in the movement assay. They were evaluated at several concentrations, and the results depicted here were obtained with 160 μM. Significant differences from the control (DMSO) group are indicated with asterisks (** p < 0.01) in this figure. c The antidepressant drugs amitriptyline (Ami), amoxapine (Amox), fluoxetine (Fluox), and trazodone (Traz) and the atypical antipsychotic loxapine (Lox) were tested for their ability to correct spontaneous movement. The data depicted here were obtained with a drug concentration of 160 μM. Significant differences are indicated by asterisks (** p < 0.01).